Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND-1: ANV600 with or without pembrolizumab in advanced solid tumors
2023-509633-39-00Phase 2Completed
- Sponsor
- Anaveon
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of ANV600 in Nonhematologic neoplasms (2 arms), sponsored by Anaveon. Primary endpoints: Incidence of dose limiting toxicities (DLT) in Phase I, Frequency and severity of treatment-emergent adverse events (TEAEs) in Phase I and 2 more. Started Jul 2024; status: completed.
02
Drugs
ANV600
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-509633-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509633-39-00.